Target
CD79b
10 abstracts
Abstract
Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL).Org: UPMC Hillman Cancer Center, University of Pittsburgh, University of Miami/Sylvester Comprehensive Cancer Center, Fred Hutchinson Cancer Center, University of Washington, Mississauga, ON, Canada,
Abstract
A phase 1 study of SHR-A1912, a CD79b targeted antibody-drug conjugate (ADC), in patients (pts) with B-cell non-Hodgkin lymphoma (B-NHL).Org: Department of Lymphoma Oncology, Shandong Cancer Hospital and Institute, Jinan, China, Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China, Phase I Clinical Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, Department of Lymphoma & Hematology, Hunan Cancer Hospital, Changsha, China, Department of Hematology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China,
Abstract
Genomic profiling in a subgroup analysis of patients (pts) with diffuse large B-cell lymphoma (DLBCL) and extranodal (EN) sites of involvement in the phase 3 Pola-R-CHP versus R-CHOP (POLARIX) study.Org: Centre Henri-Becquerel and University of Rouen, University Hospital Münster, M.D. Anderson Cancer Center, Charles University General Hospital, University of Montpellier,
Abstract
Intracellular retention of TCRαβ/CD3 and CD7 to generate novel allogeneic CAR-T cells targeting CD7 for treating T-cell malignancies.Org: Fundamenta Therapeutics Co., Ltd.,
Abstract
Safety and efficacy of CD7-CAR-T cell in patients with relapsed/refractory T-lymphoblastic leukemia/lymphoma: Phase I dose-escalation/dose-expansion study.Org: Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Lymphoma Diagnosis and Treatment Center of Henan Province, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, PersonGen-Anke Cellular Therapeutics Co., Ltd.,
Abstract
Real-world outcomes with novel therapies in R/R DLBCL.Org: Dana-Farber Cancer Institute, Genmab US, Inc., AbbVie Inc., North Chicago, IL,
Abstract
Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study.Org: Levine Cancer Institute, Wilmot Cancer Institute, BC Cancer Centre for Lymphoid Cancer, Willamette Valley Cancer Institute and Research Center, US Oncology Research,
Abstract
SUNMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.Org: MD Anderson Cancer Center, Brown University - Lifespan Cancer Institute, Hospital de Clinicas de Porto Alegre, Samsung Medical Center, Pusan National University Hospital,
Abstract
Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (LOTIS-7).Org: Blood and Marrow Transplant Group of Georgia, Virginia Cancer Specialists, ADC Therapeutics America, Inc., Institute of Hematology “Seràgnoli”, Oxford University Hospitals, NHS Trust,
Abstract
Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study.Org: The Peter MacCallum Cancer Centre, Royal Melbourne Hospital, The University of Melbourne, Department of Internal Medicine III, University Hospital Ulm, Klinik für Innere Medizin I, Hämatologie, Onkologie und Stammzelltransplantation Centrum für Chronische Immundefizienz (CCI),